The role of antiplatelet agents in the management of patients receiving intracardiac closure devices

Current Pharmaceutical Design

Volumn 12, Issue 10, 2006, Pages 1287-1291

  Franke, Andreas ^a   Kühl, Harald P ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Acetyl salicylic acid; Anticoagulation therapy; Atrial septal defects (ASD); Thrombi; Transesophageal echo cardiography

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; WARFARIN; FIBRINOLYTIC AGENT;

ANTICOAGULANT THERAPY; BLOOD CLOTTING TIME; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY STENT; DEVICE REMOVAL; DRUG DOSE REGIMEN; DRUG EFFICACY; ENDOPROSTHESIS; FOLLOW UP; HEART ATRIUM SEPTUM DEFECT; HEART CATHETERIZATION; HUMAN; INTERMETHOD COMPARISON; INTRACARDIAC THROMBOSIS; NONHUMAN; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; THROMBOGENESIS; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT DURATION; CONGENITAL HEART MALFORMATION; HEART ASSIST DEVICE; PEROPERATIVE COMPLICATION; THROMBOSIS;

FIBRINOLYTIC AGENTS; HEART DEFECTS, CONGENITAL; HEART-ASSIST DEVICES; HUMANS; INTRAOPERATIVE COMPLICATIONS; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; THROMBOSIS;

EID: 33745007126     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206776361309     Document Type: Review

References (35)

1. Hess J. Transcatheter closure of patent ductus arteriosus. Eur Heart J 1997; 18: 359-60.
2. Masura J, Walsh KP, Thanopoulous B, Chan C, Bass J, Goussous Y, et al. Catheter closure of moderate- to large-sized patent ductus arteriosus using the new Amplatzer duct occluder: immediate and short-term results. J Am Coll Cardiol 1998; 31: 878-82.
3. Schrader R, Hofstetter R, Fassbender D, Berger F, Bubmann WD, Ernst JM, et al. Transvenous closure of patent ductus arteriosus with Ivalon plugs. Multicenter experience with a new technique. Invest Radiol 1999, 34: 65-70.
4. Tofeig M, Patel RG, Walsh KP. Transcatheter closure of a mid-muscular ventricular septal defect with an amplatzer VSD occluder device. Heart 1999; 81: 438-40.
5. Thanopoulos BD, Tsaousis GS, Karanasios E, Eleftherakis NG, Paphitis C. Transcatheter closure of perimembranous ventricular septal defects with the Amplatzer asymmetric ventricular septal defect occluder: preliminary experience in children. Heart 2003; 89: 918-22.
6. Holzer R, Balzer D, Cao QL, Lock K, Hijazi ZM. Device closure of muscular ventricular septal defects using the Amplatzer muscular ventricular septal defect occluder: immediate and mid-term results of a U.S. registry. J Am Coll Cardiol 2004; 43: 1257-63.
7. Harper RW, Mottram PM, McGaw DJ. Closure of secundum atrial septal defects with the Amplatzer septal occluder device: techniques and problems. Catheter Cardiovasc Interv 2002; 57: 508-24.
8. Ende DJ, Chopra PS, Rao PS. Transcatheter closure of atrial septal defect or patent foramen ovale with the buttoned device for prevention of recurrence of paradoxic embolism. Am J Cardiol 1996; 78: 233-6.
9. Windecker S, Wahl A, Chatterjee T, Garachemani A, Eberli FR, Seiler C, et al. Percutaneous closure of patent foramen ovale in patients with paradoxical embolism: long-term risk of recurrent thromboembolic events. Circulation 2000; 101: 893-8.
10. Hung J, Landzberg MJ, Jenkins KJ, King ME, Lock JE, Palacios IF, et al. Closure of patent foramen ovale for paradoxical emboli: intermediate-term risk of recurrent neurological events following transcatheter device placement. J Am Coll Cardiol 2000; 35: 1311-6.
11. Braun M, Gliech V, Boscheri A, Schoen S, Gahn G, Reichmann H, et al. Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism. Periprocedural safety and mid-term follow-up results of three different device occluder systems. Eur Heart J 2004; 25: 424-30.
12. Sievert H, Horvath K, Zadan E, Krumsdorf U, Fach A, Merle H, et al. Patent foramen ovale closure in patients with transient ischemia attack/ stroke. J Interv Cardiol 2001; 14: 261-6.
13. Brandt RR, Neumann T, Neuzner J, Rau M, Faude I, Hamm CW. Transcatheter closure of atrial septal defect and patent foramen ovale in adult patients using the Amplatzer occlusion device: no evidence for thrombus deposition with antiplatelet agents. J Am Soc Echocardiogr 2002; 15: 1094-8.
14. Anzai H, Child J, Natterson B, Krivokapich J, Fishbein MC, Chan VK, et al. Incidence of thrombus formation on the CardioSEAL and the Amplatzer interatrial closure devices. Am J Cardiol 2004; 93: 426-31.
15. Rickers C, Hamm C, Stern H, Hofmann T, Franzen O, Schrader R, et al. Percutaneous closure of secundum atrial septal defect with a new self centering device ("angel wings"). Heart 1998; 80: 517-21.
16. Sherman JM, Hagler DJ, Cetta F. Thrombosis after septal closure device placement: A review of the current literature. Catheter Cardiovasc Interv 2004; 63: 486-9.
17. Krumsdorf U, Ostermayer S, Billinger K, Trepels T, Zadan E, Horvath K, et al. Incidence and clinical course of thrombus formation on atrial septal defect and patient foramen ovale closure devices in 1,000 consecutive patients. J Am Coll Cardiol 2004; 43: 302-9.
18. K Kuhn MA, Latson LA, Cheatham JP, McManus B, Anderson JM, Kilzer KL, et al. Biological response to Bard Clamshell Septal Occluders in the canine heart. Circulation 1996; 93: 1459-63.
19. Sievert H, Babic UU, Hausdorf G, Schneider M, Hopp HW, Pfeiffer D, et al. Transcatheter closure of atrial septal defect and patent foramen ovale with ASDOS device (a multi-institutional European trial). Am J Cardiol 1998; 82: 1405-13.
20. La Rosee K, Deutsch HJ, Schnabel P, Schneider CA, Burkhard-Meier C, Hopp HW. Thrombus formation after transcatheter closure of atrial septal defect. Am J Cardiol 1999; 84: 356-9, A9.
21. Chan KC, Godman MJ, Walsh K, Wilson N, Redington A, Gibbs JL. Transcatheter closure of atrial septal defect and interatrial communications with a new self expanding nitinol double disc device (Amplatzer septal occluder): multicentre UK experience. Heart 1999; 82: 300-6.
22. Chessa M, Carminati M, Butera G, Bini RM, Drago M, Rosti L, et al. Early and late complications associated with transcatheter occlusion of secundum atrial septal defect. J Am Coll Cardiol 2002; 39: 1061-5.
23. Martin F, Sanchez PL, Doherty E, Colon-Hernandez PJ, Delgado G, Inglessis I, et al. Percutaneous transcatheter closure of patent foramen ovale in patients with paradoxical embolism. Circulation 2002; 106: 1121-6.
24. Khositseth A, Cabalka AK, Sweeney JP, Fortuin FD, Reeder GS, Connolly HM, et al. Transcatheter Amplatzer device closure of atrial septal defect and patent foramen ovale in patients with presumed paradoxical embolism. Mayo Clin Proc 2004; 79: 35-41.
25. Bohm J, Bittigau K, Kohler F, Baumann G, Konertz W. Surgical removal of atrial septal defect occlusion system-devices. Eur J Cardiothorac Surg 1997; 12: 869-72.
26. Gastmann O, Werner GS, Babic UU, Figulla HR. Thrombus formation on transcatheter ASD occluder device in a patient with coagulation factor XII deficiency. Cathet Cardiovasc Diagn 1998; 43: 81-3.
27. Khatchatourov G, Kalangos A, Anwar A, Urban P, De Moerloose P, Friedli B, et al. Massive Thromboembolism Due to Transcatheter ASD Closure with ASDOS Device. J Invasive Cardiol 1999; 11: 743-5.
28. Fabricius AM, Krueger M, Falk V, Hanke M, Mohr FW. Floating thrombus on an ASD occluder device in a patient with hemophilia A. Thorac Cardiovasc Surg 2001; 49: 312-3.
29. Vanderheyden M, Willaert W, Claessens P, Branders I, Ex P, Vermeersch P. Thrombosis of a patent foramen ovale closure device: thrombolytic management. Catheter Cardiovasc Interv 2002; 56: 522-6.
30. La Rosee K, Krause D, Backer M, Beuckelmann DJ, Deutsch HJ, Hopp HW. [Transcatheter closure of atrial septal defects in adults. Practicality and safety of four different closure systems used in 102 patients]. Dtsch Med Wochenschr 2001; 126: 1030-6.
31. Acar P, Aggoun Y, Abdel-Massih T. Images in cardiology: Thrombus after transcatheter closure of ASD with an Amplatzer septal occluder assessed by three dimensional echocardiographic reconstruction. Heart 2002; 88: 52.
32. Willcoxson FE, Thomson JD, Gibbs JL. Successful treatment of left atrial disk thrombus on an Amplatzer atrial septal defect occluder with abciximab and heparin. Heart 2004; 90: e30.
33. Clement DL, De Buyzere ML, Duprez DA. Hypertension in peripheral arterial disease. Curr Pharm Des 2004; 10(29): 3615-20.
34. Curtin R, Intravenous glycoprotein IIb/IIIa antagonists: their benefits, problems and future developments. Curr Pharm Des 2004; 10(14): 1577-85.
35. Watala C. Blood platelet reactivity and its pharmacological modulation in (people with) diabetes mellitus. Curr Pharm Des 2005; 11(18): 2331-65.